Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report.
Fifteen patients with advanced stage D hormone-resistant prostate cancer were treated with the combination of doxorubicin, mitomycin, and 5-FU. Nine patients (60%) had objective responses, with a mean duration of 27.9 weeks. No responding patient had relapsed. Although three patients developed a culture-negative leukopenic fever, no deaths from chemotherapy occurred. Preliminary results with doxorubicin, mitomycin, and 5-FU indicate that this is a very effective chemotherapy regimen, resulting in a high objective response rate in metastatic prostate cancer.
D000230:Adenocarcinoma / Q000188:drug therapy*; D001859:Bone Neoplasms / Q000556:secondary; D004317:Doxorubicin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008937:Mitomycins / Q000008:administration & dosage*; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D008937:Mitomycins; D004317:Doxorubicin; D005472:Fluorouracil